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AbsTrACT
background semantic dementia (sD) is a 
neurodegenerative disorder characterised by 
progressive language problems falling within the 
clinicopathological spectrum of frontotemporal lobar 
degeneration (FTLD). The development of disease-
modifying agents may be facilitated by the relative 
clinical and pathological homogeneity of sD, but we 
need robust monitoring biomarkers to measure their 
efficacy. In different FTLD subtypes, neurofilament 
light chain (NfL) is a promising marker, therefore we 
investigated the utility of cerebrospinal fluid (csF) NfL 
in sD.
Methods This large retrospective multicentre study 
compared cross-sectional csF NfL levels of 162 
patients with sD with 65 controls. csF NfL levels of 
patients were correlated with clinical parameters 
(including survival), neuropsychological test scores and 
regional grey matter atrophy (including longitudinal 
data in a subset).
results csF NfL levels were significantly higher in 
patients with sD (median: 2326 pg/mL, IQR: 1628–
3593) than in controls (577 (446–766), p<0.001). 
higher csF NfL levels were moderately associated 
with naming impairment as measured by the Boston 
Naming Test (rs=−0.32, p=0.002) and with smaller 
grey matter volume of the parahippocampal gyri 
(rs=−0.31, p=0.004). however, cross-sectional csF NfL 
levels were not associated with progression of grey 
matter atrophy and did not predict survival.
Conclusion csF NfL is a promising biomarker in the 
diagnostic process of sD, although it has limited cross-
sectional monitoring or prognostic abilities.
INTroduCTIoN
Semantic dementia (SD) is a sporadic neuro-
degenerative disorder characterised by loss of 
semantic knowledge, impaired naming and word 
comprehension, with preserved speech produc-
tion.1 Compared with other disorders in the 
frontotemporal lobar degeneration (FTLD) spec-
trum, SD is relatively homogeneous because of 
the typical clinical presentation, the neuroim-
aging signature of asymmetrical anteroinferior 
temporal atrophy and the typical pathology of 
type C FTLD with TAR DNA binding protein 
43 kDa inclusions (FTLD-TDP).1–3 This homo-
geneity provides opportunities for the devel-
opment of disease-modifying agents, for which 
reliable biomarkers are essential to measure their 
efficacy.
A promising biomarker in frontotemporal 
dementia (FTD) is neurofilament light chain 
(NfL), a major component of the neuronal cyto-
skeleton involved in axonal and dendritic growth, 
signalling and transport.4 Previous studies have 
demonstrated elevated cerebrospinal fluid (CSF) 
NfL levels across the FTLD spectrum which are 
associated with disease severity, brain atrophy 
and survival.5–11 Moreover, CSF and serum NfL 
levels are strongly correlated, enabling repeated 
measurements in serum to assess disease progres-
sion or treatment response.5 12 Small series have 
shown high CSF and serum NfL concentrations 
exclusively in the group of patients with SD,7 13–15 
but a larger cohort may be needed to detect asso-
ciations with clinical variables. Another inter-
esting question in this context is whether high 
NfL levels are also associated with survival in SD, 
considering that SD is a relatively slow progres-
sive disease.16 17
In a large series of patients with SD from 14 
different centres, we investigated our hypoth-
esis that CSF NfL levels are elevated compared 
with controls and correlate with disease severity, 
atrophy and clinical progression in SD.
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Figure 1 Flowchart of patients with sD included and excluded per analysis. In total, 162 patients with sD were studied after exclusion of six patients with 
a csF profile suggestive of alzheimer’s disease, of which 87 were included in the cross-sectional imaging associations and 32 in the longitudinal imaging 
associations; reasons for exclusion are displayed in the upper boxes. The number of patients included in the associations with cognitive screeners and 
neuropsychological tests is displayed in the lower boxes; this is based on the availability of these measures within 6 months of csF sampling. BNT, Boston 
Naming Test; cDR, clinical Dementia Rating scale; cDR-sB, cDR-sum of boxes; csF, cerebrospinal fluid; FTD, frontotemporal dementia; MMse, Mini-Mental 
state examination; scWT, stroop color-Word Task; sD, semantic dementia; TMT, Trail-making Test.
MeThods
subjects
In total, 168 patients with SD with one CSF collection from 
14 different centres in Europe and the USA (numbers per site 
in online supplementary table 1) were retrospectively included 
in this study. Patients with a CSF profile suggestive of Alzhei-
mer’s pathology (a combination of low amyloid-β1-42 and high 
phospho-tau and/or total-tau,18 according to local references at 
time of CSF collection), were excluded from the study (n=6). 
Patients initially presented with language difficulties, character-
ised by fluent speech with impaired naming and word compre-
hension. The clinical diagnosis of SD was established using the 
international consensus criteria at the time of inclusion (either 
based on Neary et al. in those cases diagnosed before 2011 or 
Gorno-Tempini et al. from 2011 onwards).3 19 Some behavioural 
disturbances were present in a subset of patients (n=63), but 
language problems were the most prominent initial features in 
all. In addition to the clinical diagnosis of SD, the other inclusion 
criteria were: availability of CSF NfL concentrations (n=162) 
and survival (n=157), neuropsychological (n=147) and/or 
neuroimaging data available for analysis (n=87).
Asymmetric temporal atrophy on neuroimaging was used as 
a supportive feature; this was present in 141 patients (left-sided 
dominant atrophy in 108 patients; right-sided dominant atrophy 
in 33 patients). The remaining 21 patients with CSF NfL concen-
trations fulfilled the clinical diagnostic criteria of SD, but had no 
neuroimaging available (n=18) or had bilateral atrophy (n=3). 
TDP-pathology was confirmed in all seven deceased patients 
with brain autopsy.
To compare NfL levels between controls and patients with 
SD, 65 sex-matched and age-matched healthy controls from 
our previous studies were included.5 7 Controls had normal 
CSF amyloid-β1-42 levels and had either normal neurological 
examinations, neuropsychological testing scores and Clinical 
Dementia Rating (CDR) scores of 0 (n=44) or they were cogni-
tively healthy family members without a mutation or spouses 
from patients with genetic FTD or a different neurodegenerative 
dementia (n=21).
Disease duration was defined as time between first symptoms 
noted by a caregiver (onset) and CSF collection. Survival was 
defined as time between CSF collection and death.
standard protocol approvals, registrations and patient 
consents
The local ethics committees approved the study and all subjects 
or their legal representatives provided written informed consent.
Neuropsychological assessment
Most subjects (n=147) underwent global cognitive screening 
and/or neuropsychological assessment (NPA) at the local study 
site (for numbers per test, see figure 1); only assessments within 6 
months of CSF collection were analysed. Screening instruments 
included the Mini-Mental State Examination (MMSE), global 
CDR scale, CDR-sum of boxes (CDR-SB) and the FTD-CDR-SB. 
When follow-up scores were available, annual progression rate 
after CSF collection was calculated by the change in MMSE, 
CDR, CDR-SB or FTD-CDR-SB divided by the number of years 
between baseline and follow-up (at least 6 months).20–22
NPA batteries differed across the sites, and tests were only 
included when available in at least 30 patients (figure 1). A 
proportion of the test scores were transformed to uniformly and 
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meaningfully combine different tests or versions, and thus use 
the maximal amount of neuropsychological data. Short versions 
of the Boston Naming Test (BNT) were multiplied to match the 
total possible score of the full 60-item version. Trail-making Test-
part A (TMT-A) and part B (TMT-B) were truncated to 300 s for 
patients that exceeded the time limit of 300 s. For the Stroop 
Color-Word Test (SCWT), some versions scored the number of 
correct items within a set time, whereas others obtained the time 
to complete 50 or 100 items. We transformed all scores into 
the number of seconds needed to complete a 100-item version; 
for SCWT versions that scored the number of correct items, we 
used the following formula: number of seconds allowed * 100/
number of correct items. Next, the interference score (score on 
interference card/score on colour naming) was calculated for 
all SCWTs and used for analysis. Different word-list learning 
tasks were transformed into a percentage of correct items (Rey 
Auditory Verbal Learning Test n=34, California Verbal Learning 
Test n=24, CERAD word list memory test n=2). In addition, 
we converted scores on different versions of the Clock Drawing 
Test (CDT) to percentages. Non-transformed tests included cate-
gorical fluency (animal naming), verbal fluency (three letters), 
digit span (forward+backward) and the Rey complex figure test.
CsF analyses
CSF was collected and stored according to standardised local 
procedures. NfL was measured in duplicates by the ELISA (Uman 
Diagnostics, Umeå, Sweden) according to the manufacturer’s 
instructions. Measurements were performed in three different 
laboratories: the Amsterdam University Medical Center (135 
patients with SD, 21 controls), Bristol Myers Squib, Wallingford, 
Connecticut, USA (19 patients with SD and 44 controls) and the 
Washington University School of Medicine (8 patients with SD). 
All laboratories used the same ELISA, but the latter two added 
a dilution step (1:3 diluted, instead of 1:1 as the manual stipu-
lates). Thus, considering the optimal linearity of the assay used,23 
a correction factor of two was used for all NfL levels determined 
at these sites, resulting in comparable CSF NfL levels in patients 
across the different laboratories (p=0.09). Controls from labo-
ratory two had slightly lower NfL concentrations, but with over-
lapping ranges (laboratory 1 (Amsterdam UMC): median 800 
pg/mL, range 548–1093 pg/mL; laboratory 2 (Bristol Myers 
Squib): median 511 pg/mL, range 99–1047 pg/mL). We covaried 
analyses for each laboratory. Within all laboratories, the inter-
assay coefficient of variation was within the acceptance criteria 
(≤20%). The mean intra-assay coefficient of variation was 1.4% 
(range 0%–11.3%, unavailable in 25 patients).
Magnetic resonance imaging (MrI)
In 87 patients, structural T1-weighted (T1w) 3T MR-images 
within 6 months of CSF collection were available for neuroim-
aging analysis (mean CSF-MRI interval 0±1 months), and in 
32 patients a follow-up scan ≥6 months was available (mean 
interval between scans 13.5±7.0 months). Brain images were 
acquired locally and scans from a scanner that only contributed 
one or two scans were excluded, resulting in datasets from nine 
different scanners; detailed information on numbers and reasons 
for exclusion are presented in figure 1.
The T1w images were processed according to procedures 
described by Bron et al.24 In short, a multiatlas approach was 
used to calculate grey matter (GM) volume (mL) in 83 regions 
of interest (ROIs) from each subject’s T1w images. The unified 
tissue segmentation method25 of SPM8 (Statistical Parametric 
Mapping, London, UK) was used to segment T1w images into 
GM, white matter and CSF. Then, ROIs were defined for each 
subject by using a multiatlas approach containing 30 labelled 
T1w images with 83 ROIs each.26 27 A rigid, affine and non-rigid 
B-spline transformation model was used to register the atlas’ 
T1w images to the subjects’ T1w images. All images were masked 
with the brain extraction tool28 and non-uniformity corrected, 
after which a majority-voting algorithm was used to fuse ROI 
labels. We selected 11 specific cortical ROIs for further analysis 
from the 83 ROIs previously implicated in SD1 29 30 Processed 
images were visually inspected for each subject and each 
processing step; six scans had extensive segmentation errors and 
were therefore excluded (figure 1). For the 11 ROIs, processed 
images with outlying volumes (<25th percentile – 1.5 * IQR or 
>75th percentile + 1.5 * IQR) were closely inspected by three 
raters; if consensus was reached that the outlier was caused by a 
segmentation error, the specific ROI was excluded from analysis.
Since SD is an asymmetric disorder, GM ROIs of the domi-
nant brain side (most atrophied, based on the smallest temporal 
lobar GM volume for each patient on the baseline scan) were 
used for analysis; secondary analyses were undertaken on bilateral 
GM ROIs. All ROIs were corrected for head size by normalising 
to intracranial volume (ICV) and reported as percentage of ICV. 
The degree of asymmetry was assessed by calculating the ratio 
of temporal lobar GM volume from the dominant side to that of 
the non-dominant side, yielding a smaller ratio when more asym-
metry was present. For follow-up images, progression of atrophy 
was assessed by change in volume (mL) per year uncorrected for 
ICV: (volume follow-up – volume baseline)/interval between scans 
(years).
statistical analyses
SPSS Statistics 21.0 for Windows (Armonk, New York, USA) 
was used to analyse the data. Statistical significance was set at 
p<0.05 and Bonferroni correction for multiple testing was used 
when appropriate. Continuous data were compared between 
two groups by Mann-Whitney U or t-tests where appropriate; 
categorical variables were compared by χ² tests. CSF NfL levels 
were normalised by log transformation and compared between 
patients with SD with controls using analysis of covariance, 
correcting for sex, age at CSF collection and laboratory of NfL 
measurement. Diagnostic performance was assessed by receiver 
operating characteristic analysis, with optimal cut-off levels at 
the highest Youden index.
Spearman’s correlation coefficient (rs) was used to correlate 
non-transformed NfL levels with age at CSF collection, disease 
duration at CSF collection, cognitive screening scales (MMSE, 
CDR-SB and FTD-CDR-SB), neuropsychological tests and GM 
ROIs. Next, multivariate linear regression analysis (β) was also used 
to assess the association between (1) non-transformed NfL levels 
(independent variable) and neuropsychological tests (dependent 
variable), correcting for age, sex and laboratory and (2) non-trans-
formed NfL levels and GM ROIs, correcting for age, sex, labora-
tory and scanner. The Bonferroni method was used for correction 
for multiple comparisons. NfL as predictor for survival (after CSF 
collection) in patients was analysed using the Log Rank test and 
Kaplan-Meier curves comparing NfL tertiles, and a Cox regression 
with correction for age, sex and laboratory, both on tertiles and 
NfL as continuous variable.
resulTs
demographical and clinical data
The group of 162 patients with SD and 65 healthy controls did 
not differ in age or sex (table 1). The median disease duration at 
CSF collection in patients with SD was 3.3 years, ranging from 
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Figure 2 csF NfL concentrations in patients with sD and controls. The 
horizontal lines represent the median per group. csF, cerebrospinal fluid; 
NfL, neurofilament light chain; sD, semantic dementia; ***p<0.001.
Table 1 Subject characteristics
Patients with sd, n=162 Controls, n=65 P value
Sex, n male (%) 75 (46%) 32 (49%) 0.69
Age at CSF 
collection, years
64 (58–68) 65 (60–70) 0.43
Age at onset, 
years
60 (54–65)* n/a n/a
Age at death, 
years
69 (65–74)† n/a n/a
MMSE score 25 (21–28)‡ n/a n/a
CDR-SB score 3.5 (2.5–4.8)§ n/a n/a
FTD-CDR-SB score 4.0 (2.0–6.0)¶ n/a n/a
CSF NfL, pg/mL 2326 (1628–3593) 577 (446–766) <0.001
Isolated decreased 
abeta, n (%)
8 (5%) n/a n/a
Isolated increased 
p-tau and/or t-tau, 
n (%)
61 (38%) n/a n/a
MRI available 
at baseline (at 
follow-up), n
87 (32) n/a n/a
Continuous variables are presented as medians (IQR).
*Unknown in five patients.
†30 patients were known to be deceased at time of data analysis.
‡Available in 135 patients.
§Available in 65 patients.
¶Available in 34 patients.
CDR-SB, Clinical Dementia Rating scale sum of boxes; CSF, cerebrospinal fluid; FTD-
CDR-SB, frontotemporal dementia CDR-SB; MMSE, Mini-Mental State Examination; 
NfL, neurofilament light chain; SD, semantic dementia; abeta, amyloid-β1-42; p-tau 
and/or t-tau, phospho-tau and/or total-tau.
0.3 to 15.2 years. The FTD-CDR-SB scores in patients with SD 
ranged from 1.0 to 22.0 with a median of 4.0 (n=34). Available 
neuropsychological data showed poor performances on the BNT 
(mean=20, n=89) and verbal fluency tasks (semantic fluency: 
mean=8, n=110; phonological fluency: mean=21, n=66). 
The median follow-up of living patients was 4.1 years (range 
0.6–13.6, n=127; five patients were lost to follow-up) while 
median survival of deceased patients after CSF collection was 
5.3 years (range 1.0–14.1, n=30).
Nfl in relation to clinical characteristics and 
neuropsychological test scores
CSF NfL levels were higher in patients with SD than in 
controls (table 1, figure 2, p<0.001) and had a sensitivity of 
93% and a specificity of 98% (cut-off level 1049 pg/mL, area 
under the curve 0.98 (95% CI 0.96 to 1.00)). Cross-sectional 
NfL correlated with the BNT (table 2, figure 3A, rs=−0.32, 
p=0.002), trended towards an association with annual change of 
MMSE (table 3, uncorrected p=0.04), but not with age, disease 
duration at CSF collection, cross-sectional MMSE, CDR-SB or 
FTD-CDR-SB. TMT-A and TMT-B trended towards association 
with NfL (table 2), and this was however confounded by age 
(multivariate regression).
Association between Nfl and regional GM volumes
CSF NfL levels were negatively associated with GM volume 
of the parahippocampal gyrus on the dominant atrophic side 
(table 4, figure 3B, rs=−0.31, p=0.003), and there was a trend 
for association with GM volume of the medial and inferior 
temporal gyri (rs=−0.28, p=0.06). Cross-sectional NfL levels 
did not correlate with progression of atrophy in the selected 
ROIs in the small series of patients with SD with follow-up scans 
(n=32) (table 4). When the analyses were repeated with bilateral 
volumes, a negative association with the parahippocampal gyri 
was found once again (rs=−0.32, p=0.003). Additionally, the 
bilateral medial and inferior temporal gyri, temporal pole and 
hippocampus were negatively associated with NfL; however, 
after correction for covariates, the association did not withstand 
Bonferroni correction.
survival analyses
Cox regression analysis with cross-sectional CSF NfL as a 
continuous variable showed a trend for association between NfL 
levels and survival (p=0.06, HR 1.22 (95% CI 0.99 to 1.51)). 
However, CSF NfL tertiles did not associate with survival after 
CSF collection (figure 3C, p=0.66 log rank test, p=0.80 Cox 
regression with correction for sex, age and laboratory). Excluding 
patients with an outlying long disease duration (>Q3+1.5*IQR) 
yielded the same results.
dIsCussIoN
This large international multicentre SD study shows that the clin-
ical value of cross-sectional CSF NfL differs from other FTLD 
subtypes noted in previous reports. Increased CSF NfL levels 
in patients with SD were associated with more severe naming 
impairment and smaller GM volume of the parahippocampal 
gyrus, both with a medium effect size (correlation coefficient of 
−0.3). In contrast to other FTLD subtypes, NfL did not asso-
ciate with progression of GM atrophy or survival.
The elevated CSF NfL levels in patients with SD compared 
with controls is in line with those found in previous smaller 
SD series.7 12–14 The absence of a correlation between CSF 
NfL and age is probably caused by the disease effect overriding 
the age effect. The observed association between higher NfL 
levels and worse performance on the BNT may suggest that 
the variance in NfL is partly determined by disease severity, 
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Table 2 Associations between neurofilament light chain and neuropsychological test scores
Test
Correlation Multivariate regression
N rs P value β P value
BNT 89 −0.32 0.002* −0.34 0.002*
Categorical fluency 110 −0.17 0.08 −0.14 0.14
Letter fluency 66 −0.03 0.83 −0.14† 0.28
Digit span 107 0.07 0.47 0.04 0.71
TMT-A 84 −0.23 0.04 −0.20† 0.07
TMT-B 78 −0.30 0.007 −0.19† 0.09
SCWT interference ratio 52 0.12 0.39 0.08‡ 0.57
Word list immediate recall 60 −0.17 0.20 −0.22§ 0.08
Word list delayed recall 60 −0.23 0.07 −0.24§ 0.08
Clock drawing test 30 0.23 0.23 0.21† 0.30
Rey figure copy 50 −0.05 0.71 0.04† 0.76
Rey figure delayed recall 44 −0.17 0.27 −0.24† 0.10
Multivariate regression is corrected for age, gender and laboratory. P<0.05 are in bold.
*Survived Bonferroni correction for multiple testing (p<0.004).
†Not corrected for laboratory as all samples were analysed in the same laboratory for these tests.
‡After additional correction for version seconds to complete versus number correct: β=0.15, p=0.27.
§Similar results with additional correction for test version.
BNT, Boston Naming Test; SCWT, Stroop Color-Word Task; TMT, Trail-making Test.
Figure 3 Relationship of csF NfL with language impairment, parahippocampal atrophy and survival in patients with sD. (a) association between NfL and 
the BNT as measure for naming impairment. When the patient (who had a right dominant sD) with a high BNT score was excluded, the analyses remained 
significant. (B) association between NfL and grey matter volume of the parahippocampal gyrus at the dominant side, displayed as percentage of IcV. (c) NfL 
was not associated with survival after csF collection in sD as exemplified by this Kaplan-Meier curve of NfL levels stratified to lowest (green line), middle 
(blue line) and highest tertiles (red line). Vertical ticks represent living patients. BNT, Boston Naming test; csF, cerebrospinal fluid; IcV, intracranial volume; 
NfL, neurofilament light chain; sD, semantic dementia.
as naming impairments and semantic deficits are hallmarks of 
SD.22 31 32 Future studies will benefit from more extensive and 
more uniform testing of word comprehension.
While earlier studies found an association of NfL with CDR 
in different FTD types,5 7 we found no association with the CDR 
in our study. This may be explained by the fact that patients 
with problems confined to language remained independent in 
daily life activities.33 The FTD-CDR-SB does include a language 
domain as one of the eight items, but the number of patients with 
data on this scale was too small to draw strong conclusions. Like-
wise, the association between NfL and future decline in MMSE 
did not survive multiple testing correction and seems—com-
bined with its medium effect size—therefore not suitable as a 
predictor for functional decline.
The significant association between higher CSF NfL levels 
and smaller parahippocampal GM volume in our study is in 
line with studies showing positive correlations with temporal 
cortical regions in FTD.5 7 This is in line with a large body of 
evidence that NfL levels reflect the extent of neuronal loss5 7 34 as 
supported by neurodegenerative mouse models.35 Of note, one 
previous study using blood found no association of GM volume 
with serum NfL in patients with SD,14 which could be explained 
by the larger power of our study, or that CSF NfL might be 
more sensitive than serum NfL.34 The parahippocampal gyrus 
is located in the core of the neurodegenerative process, which 
starts in the temporal pole and fusiform gyrus spreading to the 
orbitofrontal, inferior frontal, insular and anterior cingulate 
cortices as well as posteriorly to temporoparietal regions, and 
into homologous areas of the contralateral hemisphere.1 29 30 
More regions were (borderline) significantly associated when 
analysing bilaterally rather than at the dominant side only. 
This may point towards an important difference between these 
markers: GM atrophy represents cumulative injury, while CSF 
NfL measures the current balance between release and clearance 
of NfL and thus reflects ongoing neuronal loss. Our notable lack 
of association of NfL with the anterior temporal lobe may then 
be explained by the striking atrophy at time of presentation (as 
illustrated by figure 4) precluding further release of neurofila-
ments from this region. Other studies report that NfL levels are 
elevated during active periods of multiple sclerosis and traumatic 
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Table 3 Association between neurofilament light chain and clinical 
characteristics or global cognitive scales in patients with SD
Cross-sectional longitudinal
N rs P value N rs P value
Age at CSF collection 162 −0.002 0.98 n/a n/a n/a
Age at onset 157 −0.06 0.46 n/a n/a n/a
Disease duration at CSF 
collection
157 0.03 0.68 n/a n/a n/a
MMSE 135 −0.11 0.20 51 −0.29 0.04
Global CDR 78 0.15 0.18 33 −0.03 0.86
CDR-SB 65 0.23 0.07 33 −0.01 0.97
FTD-CDR-SB 34 0.05 0.79 10 0.33 0.37
For longitudinal analysis, annualised change of the scores was used. P<0.05 are in 
bold, none survived Bonferroni correction for multiple testing.
CDR, global score of clinical dementia rating scale; CDR-SB, clinical dementia rating 
scale sum of boxes; CSF, cerebrospinal fluid; FTD-CDR, frontotemporal dementia 
clinical dementia rating scale; MMSE, Mini-Mental State Examination.
Table 4 Associations between neurofilament light chain and grey matter regions of interest of the dominant side*
region of interest
Cross-sectional (n=87) longitudinal (n=32)
Correlation Multivariate regression Correlation Multivariate regression
rs P value β P value rs P value β P value
Temporal pole† −0.13 0.24 −0.13 0.27 −0.11 0.57 −0.11 0.63
Medial and inferior temporal gyri −0.28 0.009 −0.21 0.06 0.03 0.88 −0.29 0.16
Superior temporal gyrus, central part −0.17 0.11 −0.16 0.16 −0.01 0.94 −0.07 0.72
Fusiform gyrus −0.16 0.14 −0.18 0.12 −0.33 0.07 −0.34 0.08
Parahippocampal gyrus −0.31 0.004‡ −0.33 0.003‡ 0.08 0.67 −0.04 0.85
Hippocampus −0.20 0.07 −0.20 0.08 0.02 0.93 0.06 0.80
Amygdala −0.18 0.09 −0.19 0.09 0.12 0.54 0.08 0.69
Insula −0.19 0.07 −0.17 0.13 −0.09 0.62 0.04 0.82
Orbitofrontal cortex§ −0.05 0.62 −0.05 0.67 0.10 0.59 0.17 0.40
Inferior frontal gyrus −0.03 0.78 0.04 0.76 0.09 0.61 0.03 0.87
Anterior cingulate gyrus¶ −0.02 0.89 0.07 0.56 0.00 1.00 −0.02 0.91
Association of neurofilament light chain with gray matter regions of the dominant side on cross-sectional scanning and with change in volume between follow-up and baseline 
scan.
For cross-sectional associations, intracranial volume-corrected volumes were used; for longitudinal associations, the change of volume per year was used. Multivariate regression 
was corrected for age, gender, laboratory and scanner (the latter only for cross-sectional scans); P<0.05 are in bold.
*Of the patients with a usable baseline MRI scan (n=87), 65 were left-dominant while 22 were right-dominant, which indicated a strong temporal asymmetry (mean ratio 
temporal atrophy of 0.76 (±0.08).
†Combination of the medial anterior temporal lobe, lateral anterior temporal lobe and the anterior part of the superior temporal gyrus.
‡Survived Bonferroni correction for multiple testing (p<0.0045).
§Combination of the anterior, medial, lateral and posterior orbital gyri.
¶Combination of the supragenual, subgenual and presubgenual part of the anterior cingulate gyrus.
brain injury and normalise afterwards or after treatment.36 37 If 
this hypothesis on NfL release is correct, the change of NfL 
over time would associate with progression of atrophy, as has 
previously been shown for primary progressive aphasia or FTD 
subtypes combined.5 13 14 We found no association between base-
line NfL and progression of GM atrophy. This may be due to the 
relatively small subset of patients with longitudinal MRI data 
and/or to the slow decrease of GM atrophy over time. Larger 
series of longitudinal NfL levels with corresponding MRI scans 
are needed to elucidate these discrepancies, preferably including 
patients early in their disease process with multiple time-points, 
and by taking a possible non-linear relationship into account.
We showed a trend for a significant association between 
cross-sectional NfL levels and future survival in SD. This seems 
to be in contrast with the evidence of an association between 
high NfL levels and shorter survival in FTD, progressive supra-
nuclear palsy, Alzheimer’s disease (AD) and amyotrophic lateral 
sclerosis.5 6 10 11 However, the median follow-up time of the 
entire cohort in our study was 4.3 years (IQR: 2.6–6.0), which is 
relatively short considering average survival which ranges from 
9 to 12 years in SD.16 17 Since the follow-up time may have been 
too short to capture the differences in survival, we propose to 
reinvestigate the survival of the current cohort in approximately 
3–5 years.
A major strength of this study was the large international 
series of CSF samples and clinical data from patients with this 
rare disease, which comprises 10%–15% of FTD cases.16 A 
second strength was the multimodal approach in correlating NfL 
to clinical, neuropsychological and imaging data. Moreover, we 
included only one FTD subtype—after exclusion of patients with 
CSF profiles suggestive of AD, making the results specific and 
not influenced by clinical or pathological heterogeneity.
Since SD is one of the most homogeneous subtypes of FTD, 
it is a promising target for developing novel treatments. Our 
results are also important for future trials, as they suggest a 
limited role for cross-sectional CSF NfL as a monitoring or 
progression marker in SD.
The multicentre approach also caused some limitations, 
especially considering the measurement of NfL levels at three 
different centres. Unfortunately, no controls are provided in 
the ELISA kit, and due to the current lack of a quality control 
programme, the assays of the different laboratories could not be 
compared directly. We accounted for differences between labora-
tories by normalisation and laboratory-correction, but in future 
multicentre studies, harmonisation of results could be improved 
by remeasuring a number of control and patient samples across 
the different laboratories.
Other possible limitations include the different neuropsycho-
logical test batteries per centre and this might have introduced 
variability and loss of sensitivity; however, we transformed 
different versions of the same test to analyse them together. 
Furthermore, the variation in scanners and parameters of the 
T1-weighted imaging was reduced by including 3T data only, 
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Figure 4 Temporal pole atrophy in patients. Transversal T1-weighted MR images of patients representative for the distribution of dominant anterior 
temporal pole atrophy within the sample. From left to right: patient with lower quartile (a), median (B) and upper quartile (c) anterior temporal pole grey 
matter volumes of the dominant side.
excluding data from scanners on which less than three datasets 
were acquired and correcting for scanner in the analysis. Addi-
tionally, we did not study different primary progressive aphasia 
subtypes and did not include serum—which is likely to replace 
CSF measurements in the near future. The lack of longitudinal 
NfL data did not allow us to draw conclusions about NfL and 
clinical or imaging markers over time; it is conceivable that a 
plateau phase or even a decrease of NfL may occur over time.
In conclusion, our results show that cross-sectional elevated 
CSF NfL may be a useful biomarker for the neurodegenerative 
process in SD, which could lead to the use of CSF NfL as a 
diagnostic biomarker. However, the use of CSF NfL to monitor 
disease progression in SD remains debatable, since we only found 
a moderate association with language deterioration and atrophy 
and no relation of CSF NfL with survival (in a relatively short 
follow-up time). This is in contrast with previous reports on 
NfL in other neurodegenerative diseases5 6 10 11 and should thus 
be taken into account when interpreting studies that combined 
different FTLD subtypes. Recently, it has become clear that NfL 
in blood and CSF strongly correlate,5 12 facilitating longitudinal 
monitoring. More longitudinal multicentre studies are needed 
to assess how serial NfL levels fluctuate over time in relation 
to longitudinal clinical and imaging changes in SD (and other 
FTLD subpopulations) and thereby their potential utility.
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